MIT engineers at the Koch Institute used a machine-learning algorithm to screen nearly 50 FDA-approved excipients and identify lipid nanoparticle formulations that keep mRNA vaccines stable at room temperature for up to a year, or near 37C for two months. The AI approach, which also worked on Pfizer-style particles and needle-free microneedle patches, cut the formulation search from months to weeks. The work, published in Nature Biotechnology, could ease vaccine distribution in regions without reliable cold-chain infrastructure.
